Jacob Bodilsen

Jacob Bodilsen

Auto-generated profile, based on publicly available information

Jacob Bodilsen

Study Group for Infections of the Brain (ESGIB), European Society of Clinical Microbiology and Infectious Diseases, 4051 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
JBJacob Bodilsen
Jacob Bodilsen
QDQuintino Giorgio D'Alessandris
Quintino Giorgio D'Alessandris
HHHilary Humphreys
Hilary Humphreys
MIMildred A. Iro
Mildred A. Iro
MKMatthias Klein
Matthias Klein
MBMatthijs C. Brouwer
Matthijs C. Brouwer
These ESCMID guidelines are intended for clinicians involved in diagnosis and treatment of brain abscess in children and adults. Key questions were developed, and a systematic review was carried out of all studies published since January 1st, 1996, using the search terms "brain abscess" OR "cerebral abscess" as Mesh terms or text in electronic databases of PubMed, Embase, and the Cochrane registry. The search was updated on September 29th, 2022. Exclusion criteria were a sample size <10 patients or publication in non-English language. Extracted data was summarized as narrative reviews and tables. Metanalysis was carried out using a random effects model and heterogeneity was examined by I2 tests as well as funnel and Galbraith plots. Risk of bias was assessed using ROBINS-I (observational studies) and QUADAS-2 (diagnostic studies). The GRADE approach was applied to classify strength of recommendations (strong or conditional) and quality of evidence (high, moderate, low, or very low). MRI is recommended for diagnosis of brain abscess (strong, high). Antimicrobials may be withheld until aspiration or excision of brain abscess in patients without severe disease if neurosurgery can be carried out within reasonable time, preferably within 24 hours (conditional, low). Molecular-based diagnostics are recommended, if available, in patients with negative cultures (conditional, moderate). Aspiration or excision of brain abscess is recommended whenever feasible, except for cases with toxoplasmosis (strong, low). Recommended empirical antimicrobial treatment for community-acquired brain abscess in immuno-competent individuals is a 3rd generation cephalosporin and metronidazole (strong, moderate) with the addition of trimethoprim-sulfamethoxazole and voriconazole in patients with severe immuno-compromise (conditional, low). Recommended empirical treatment of post-neurosurgical brain abscess is a carbapenem combined with vancomycin or linezolid (conditional, low). The recommended duration of antimicrobial treatment is 6-8 weeks (conditional, low). No recommendation is offered for early transition to oral antimicrobials due to a lack of data, and oral consolidation treatment after ≥6 weeks of intravenous antimicrobials is not routinely recommended (conditional, very low). Adjunctive glucocorticoid treatment is recommended for treatment of severe symptoms due to perifocal oedema or impending herniation (strong, low). Primary prophylaxis with antiepileptics is not recommended (conditional, very low). Research needs are addressed.

24 May 2021 in BMJ
Verified
Journal Article
Open access
PDF file
JBJacob Bodilsen
Jacob Bodilsen
PNPeter Brønnum Nielsen
Peter Brønnum Nielsen
MSMette Søgaard
Mette Søgaard
MDMichael Dalager-Pedersen
Michael Dalager-Pedersen
LSLasse Ole Zacho Speiser
Lasse Ole Zacho Speiser
FSFlemming Skjøth
Flemming Skjøth
Objective To determine the incidence of hospital admissions and associated mortality rates for non-covid medical conditions during the covid-19 pandemic. Design Nationwide, population based cohort study. Setting Denmark from 13 March 2019 to 27 January 2021. Participants All Danish residents >1 year of age. Main outcomes measures Population based healthcare registries that encompass the entire Danish population were used to compare hospital admission and mortality rates during the covid-19 pandemic (from 11 March 2020 to 27 January 2021) with the prepandemic baseline data (from 13 March 2019 to 10 March 2020). Hospital admissions were categorised as covid-19 when patients were assigned a diagnosis code for covid-19 within five days of admission. All patients were followed until migration, death, or end of follow-up, whichever came first. Rate ratios for hospital admissions were computed using Poisson regression and were directly standardised using the Danish population on 1 January 2019 as reference. 30 day mortality rate ratios were examined by Cox regression, adjusted for age and sex, and covid-19 diagnosis was used as a competing risk. Results 5 753 179 residents were identified during 567.8 million person weeks of observation, with 1 113 705 hospital admissions among 675 447 people. Compared with the prepandemic baseline period (mean hospital admission rate 204.1 per 100 000/week), the overall hospital admission rate for non-covid-19 conditions decreased to 142.8 per 100 000/week (rate ratio 0.70, 95% confidence interval 0.66 to 0.74) after the first national lockdown, followed by a gradual return to baseline levels until the second national lockdown when it decreased to 158.3 per 100 000/week (0.78, 0.73 to 0.82). This pattern was mirrored for most major diagnosis groups except for non-covid-19 respiratory diseases, nervous system diseases, cancer, heart failure, sepsis, and non-covid-19 respiratory infections, which remained lower throughout the study period. Overall 30 day mortality rates were higher during the first national lockdown (mortality rate ratio 1.28, 95% confidence interval 1.23 to 1.32) and the second national lockdown (1.20, 1.16 to 1.24), and these results were similar across most major diagnosis groups. For non-covid-19 respiratory diseases, cancer, pneumonia, and sepsis, the 30 day mortality rate ratios were also higher between lockdown periods. Conclusions Hospital admissions for all major non-covid-19 disease groups decreased during national lockdowns compared with the prepandemic baseline period. Additionally, mortality rates were higher overall and for patients admitted to hospital with conditions such as respiratory diseases, cancer, pneumonia, and sepsis. Increased attention towards management of serious non-covid-19 medical conditions is warranted.

1 January 2020 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JBJ. Bodilsen
J. Bodilsen
MDM. Dalager-Pedersen
M. Dalager-Pedersen
DBDiekerik van de Beek
Diekerik van de Beek
MBM.C. Brouwer
M.C. Brouwer
HNH. Nielsen
H. Nielsen

9 August 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JBJacob Bodilsen
Jacob Bodilsen
MDMichael Dalager-Pedersen
Michael Dalager-Pedersen
HSHenrik Carl Schønheyder
Henrik Carl Schønheyder
HNHenrik Nielsen
Henrik Nielsen
Community-acquired bacterial meningitis (CABM) is a life-threatening disease and timing of antibiotic therapy remains crucial. We aimed to analyse the impact of antibiotic timing on the outcome of CABM in a contemporary cohort. We conducted a population-based cohort study based on chart reviews of all adult cases (>16 years of age) of CABM in North Denmark from 1998 to 2014 excluding patients given pre-hospital parenteral antibiotics. We used modified Poisson regression analyses to compute the adjusted risk ratio (adj. RR) with 95 % confidence intervals (CIs) for in-hospital mortality and unfavourable outcome at discharge by time after arrival to hospital to adequate antibiotic therapy. We identified 195 adults with CABM of whom 173 patients were eligible for further analyses. The median door-to-antibiotic time was 2.0 h (interquartile range (IQR) 1.0–5.5). We observed increased adjusted risk ratios for in-hospital mortality of 1.6 (95 % CI 0.8–3.2) and an unfavourable outcome at discharge of 1.5 (95 % CI 1.0–2.2, p = 0.03) when treatment delays exceeded 6 h versus treatment within 2 h of admission. These findings corresponded to adjusted risk ratios of in-hospital mortality of 1.1 per hour of delay (95 % CI 0.8–1.5) and an unfavourable outcome at discharge of 1.1 per hour of delay (95 % CI 1.0–1.3) within the first 6 h of admission. Some patients (31 %) were diagnosed after admission and had more delays in antibiotic therapy and correspondingly increased in-hospital mortality (30 vs 14 %, p = 0.01) and unfavourable outcome (62 vs 37 %, p = 0.002). Delay in antibiotic therapy was associated with unfavourable outcome at discharge.

27 November 2019 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
JBJacob Bodilsen
Jacob Bodilsen
MDMichael Dalager-Pedersen
Michael Dalager-Pedersen
DBDiederik van de Beek
Diederik van de Beek
MBMatthijs C Brouwer
Matthijs C Brouwer
HNHenrik Nielsen
Henrik Nielsen
Background: We aimed to determine the long-term risks of mortality and new-onset epilepsy after brain abscess. Methods: Using nationwide population-based medical registries, we examined all patients with first-time brain abscess in Denmark, 1982–2016. Comparison cohorts individually matched on age, sex, and residence were identified, as were siblings of all study participants. Next, we computed cumulative incidences and hazard rate ratios (HRRs) with 95% confidence intervals of mortality and new-onset epilepsy among study populations. Results: We identified 1384 brain abscess patients (37% females) with a median follow-up time of 5.9 years (interquartile range [IQR] 1.1–14.2). The 1-year, 2–5 year, and 6–30 year mortality of patients after brain abscess was 21%, 16%, and 27% as compared to 1%, 6%, and 20% for population controls. Cox regression analyses adjusted for Charlson comorbidity index score showed 1-year, 2–5 year, and 6–30 year HRRs of 17.5 (13.9–22.0), 2.61 (2.16–3.16), and 1.94 (1.62–2.31). The mortality in brain abscess patients was significantly increased regardless of sex or age group except among subjects 80 years or older, and in both previously healthy individuals and immunocompromised persons. Among the 30-day survivors of brain abscess (median follow-up 7.6 years [IQR 2.2–15.5]), new-onset epilepsy occurred in 32% compared to 2% in matched population controls. Cause-specific Cox regression analysis adjusted for stroke, head trauma, alcohol abuse, and cancer showed 1-year, 2–5 year, and 6–30 year HRRs for new-onset epilepsy of 155 (78.8–304), 37.7 (23.0–59.9), and 8.93 (5.62–14.2). Conclusions: Brain abscess is associated with an increased long-term risk of mortality and new-onset epilepsy for several years after infection.

29 August 2022 in Brain
Verified
Journal Article
Closed access
PDF file
JBJacob Bodilsen
Jacob Bodilsen
LDLærke Storgaard Duerlund
Lærke Storgaard Duerlund
TMTheis Mariager
Theis Mariager
CBChristian Thomas Brandt
Christian Thomas Brandt
PPPelle Trier Petersen
Pelle Trier Petersen
HLHans Rudolf von Lüttichau
Hans Rudolf von Lüttichau
Studies on brain abscess are hampered by single-centre design with limited sample size and incomplete follow-up. Thus, robust analyses on clinical prognostic factors remain scarce. This Danish nationwide, population-based cohort study included clinical details of all adults (≥18 years) diagnosed with brain abscess in the Danish National Patient Registry from 2007 through 2014 and the prospective clinical database of the Danish Study Group of Infections of the Brain covering all Danish departments of infectious diseases from 2015 through 2020. All patients were followed for 6 months after discharge. Prognostic factors for mortality at 6 months after discharge were examined by adjusted modified Poisson regression to compute relative risks (RR) with 95% confidence intervals (CI). Among 485 identified cases, the median age was 59 years (IQR 48-67) and 167 (34%) were female. The incidence of brain abscess increased from 0.4 in 2007 to 0.8 per 100,000 adults in 2020. Immuno-compromise was prevalent in 192/485 (40%) and the clinical presentation was predominated by neurological deficits 396/485 (82%), headache 270/411 (66%), and fever 208/382 (54%). The median time from admission until first brain imaging was 4.8 hours (IQR 1.4-27). Underlying conditions included dental infections 91/485 (19%) and ear-nose-throat infections 67/485 (14%), and the most frequent pathogens were oral cavity bacteria (59%), Staphylococcus aureus (6%), and Enterobacteriaceae (3%). Neurosurgical interventions comprised aspiration 356/485 (73%) or excision 7/485 (1%) and was preceded by antibiotics in 377/459 (82%). Fatal outcome increased from 29/485 (6%) at discharge to 56/485 (12%) 6 months thereafter. Adjusted RRs for mortality at 6 months after discharge was 3.48 (95% CI 1.92-6.34) for intraventricular rupture, 2.84 (95% CI 1.45-5.56) for immuno-compromise, 2.18 (95% CI 1.21-3.91) for age >65 years, 1.81 (95% CI 1.00-3.28) for abscess diameter >3 cm, and 0.31 (95% CI 0.16-0.61) for oral cavity bacteria as causative pathogen. Sex, neurosurgical treatment, antibiotics before neurosurgery, and corticosteroids were not associated with mortality. This study suggests that prevention of rupture of brain abscess is crucial. Yet, antibiotics may be withheld until neurosurgery, if planned within a reasonable time period (e.g. 24 hours), in some clinically stable patients. Adjunctive corticosteroids for symptomatic perifocal brain oedema was not associated with increased mortality.